This webinar is designed to provide a plan of action that can help to de-risk your Investigational New Drug (IND) application and expedite the path to gaining study clearance. Dr. Nick Meyers, Vice President of Product Development and Katy Rudnick, Head of US Regulatory Affairs, will take you through the IND preparation process explaining de-risking activities that save time and cost while promoting quick advancement of your product into the clinic. Thoroughly planning the strategy, timing, content, and delivery of the IND is critical to avoid unnecessary delays to your development program.